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Résumé Abstract
Cet article de revue examine les préoccupations éthiques
lors de recherches menées chez les usagers
potentiellement vulnérables de drogues injectables (PWID)
dans un contexte canadien. L’Énoncé de politique des trois
Conseils : Éthique de la recherche avec des êtres humains
aborde un large éventail de principes traditionnels de
l’éthique de la recherche concernant les personnes
vulnérables mais le fait au détriment de la clarté et de la
précision. La vulnérabilité est contextuelle plutôt
qu’absolue. Dans le cadre de recherche auprès des
personnes vulnérables, le consentement éclairé devrait
être obtenu par une personne indépendante et la
compréhension devrait être vérifiée à l’aide d’un
questionnaire. Les participants peuvent être vulnérables en
raison de nombreux facteurs, notamment la toxicomanie,
les maladies chroniques, le statut socio-économique et
ethnique et le faible niveau d’éducation. La capacité de
PWID à donner un consentement éclairé peut être
compromis par une influence indue ou une intoxication
mais les recherches existantes montrent que ni le mode ni
l’ampleur de l’indemnisation n’ont un effet significatif sur les
nouveaux taux de consommat ion de drogues.
L’indemnisation peut également contribuer à dissiper la
méprise thérapeutique. L’intoxication plutôt que l’influence
indue est la principale préoccupation lors de l’obtention du
consentement éclairé des PWID. La stigmatisation des
PWID comme incapables de consentir devrait être évitée.
L’exclusion paternaliste de la recherche peut nuire aux
PWID et exacerber leur vulnérabilité en réduisant notre
connaissance et notre capacité à les traiter spécifiquement.
En tant que tel, nous devons recueillir de meilleures
données concernant les effets des politiques d’éthique de
la recherche. Les études menées à ce sujet devraient être
axées sur les expériences, les perspectives et les besoins
des participants à la recherche qui sont potentiellement
vulnérables. Les comités d’éthique de la recherche au
Canada devraient adopter une approche fondée sur des
preuves lors de l’application du pouvoir discrétionnaire
pour les propositions en recherche clinique.
This review article considers ethical concerns when doing
research on potentially vulnerable people who inject drugs
(PWID) in a Canadian context. The Tri-Council Policy
Statement: Ethical Conduct for Research Involving
Humans broadly addresses many of the traditional ethical
principles of research on vulnerable persons, but does so
at the cost of clarity and precision. Vulnerability is
contextual rather than absolute. When doing research with
vulnerable persons, informed consent should be obtained
from an independent person, and comprehension should
be checked using questioning. Participants can be
vulnerable due to many factors, including addiction, chronic
disease, socioeconomic and racial status, and lack of
education. The ability of PWID to give informed consent
can be compromised by undue influence or intoxication, but
existing research shows that neither the mode nor the
magnitude of compensation has a significant effect on new
rates of drug use. Compensation can also help dispel the
therapeutic misconception. Intoxication rather than undue
influence is the main concern when obtaining informed
consent from PWID. The stigmatization of PWID as
incapable of consent should be avoided. Paternalistic
exclusion from research can harm PWID and exacerbate
their vulnerability by reducing our knowledge of and ability
to specifically treat them. As such, we must collect better
data about the effects of research ethics policies. Studies to
this effect should focus on experiences, perspectives and
needs of potentially vulnerable research participants.
Research ethics boards in Canada should adopt an
evidence-based approach when applying discretionary
power to proposals for clinical research.
Mots clés Keywords
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Introduction 
Intravenous drug addiction causes serious vulnerability in society, producing high rates of chronic
disease such as HIV, Hepatitis B & C and tuberculosis, as well as social deterioration and
psychological harm [1-7]. Approximately 50% of people who inject drugs (PWID) die within a 30-year
follow-up period [8]. Due to these realities, recruitment of PWID has been and continues to be of
considerable importance to clinical research; for example, decades of research with PWID has led to
many new discoveries about HIV prevention [9]. Including PWID as research participants can allow
researchers to study specific illnesses more directly, while, at the same time, potentially providing
benefits to the PWID community in the short and long term. However, ethical issues arise in these
circumstances.
The treatment of vulnerable individuals in research has been a serious concern of governments and
bioethicists ever since the public unveiling of grievous misconduct in historical clinical
experimentation. Key atrocities among those publicized were Nazi experimentation, American
research on “conscientious objectors”, the Tuskegee syphilis experiment, and American hepatitis
experimentation on disabled children [10,11]. Over the decades, most nations have enacted
legislation and/or policy guidelines requiring individuals deemed vulnerable to receive special
treatment in clinical research, or to be excluded altogether. In Canada, the treatment of vulnerable
populations in research is governed by the Canadian Panel on Research Ethics’ Tri-Council Policy
Statement on Ethical Conduct for Research Involving Humans, 2nd Edition (TCPS2), along with the
ethics committees and review boards that discretionarily apply it [12]. Researchers also self-govern
using both new developments in ethics, and existing ethical norms from domestic and international
scientific traditions. On the international scale, the World Medical Association’s (WMA) Helsinki
Declaration is a foundational document for human research ethics; it consists of a series of principles
for ethical human experimentation endorsed by the WMA’s general assembly [13]. These policies,
among many others, seek to ensure that vulnerable populations involved in research are afforded fair
and just treatment.
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In this review, we examine the existing literature on the ethics of vulnerability in research, as well as
the important vulnerability provisions of the TCPS2. Subsequently, we review issues surrounding the
ethics of research on PWID. Finally, we discuss implications of the literature, and consider criticisms
of existing ethical and regulatory frameworks in relation to PWID. We conclude with suggestions as to
a way forward for future research in vulnerable population ethics.
General Concepts in Research on Vulnerable Populations
Attempts to define vulnerability in measurable ways have met with little to no consensus [14,15].
Some reasonably suggest that vulnerability is not static, but rather indexical: not absolute, but
contextual [14,16]. The Helsinki Declaration does not define vulnerability, but states that “all
vulnerable groups and individuals should receive specifically considered protection” [13]. It also states
that medical research on a vulnerable group is only acceptable if three criteria are met: the research is
responsive to the health needs or priorities of this group, the research cannot be carried out on a non-
vulnerable group, and the group would stand to benefit from resultant knowledge, practices or
interventions [13]. These criteria seek to ensure a favourable ratio of expected benefit to burden for
vulnerable groups [17].
Informed consent is a pillar of research ethics. A person obtaining informed consent should be
independent and free from conflicts of interest [13]. The process generally consists of providing all
material information, ascertaining that this information is clearly understood, confirming capacity and
competency, and ensuring voluntariness [18]. Canadian common law further requires that in a
medical context, information related to the nature of a procedure, its risks and benefits, and alternative
treatments that a reasonable person in the patient’s position would want to know must be
disclosed [19]. Vulnerable individuals may be unable to understand information, may lack capacity, or
may be prone to experiencing undue influence or coercion that essentially renders their consent
involuntary. Because of these issues, obtaining a valid, legal consent can be a challenge. Greater
care is required to ensure that all the elements of consent are present. In addition, it is not always
possible to determine vulnerability prior to the commencement of a study, and a repetitive process
can aid in ensuring eventual identification [16]. As such, the process of obtaining informed consent
should be ongoing [16].
Ethical judgments about research are influenced by competing concepts and can often be
contradictory (e.g., a researcher’s attempt to ensure non-maleficence may lead to paternalistic
behaviour that violates the principle of respect for a participant’s autonomy) [20]. However, there is
much support for the notion that research on a vulnerable group is only justified when that group
stands to benefit from the potential results of the research [13,21,22]. If the vulnerable group does not
stand to receive any benefit, and instead the benefit will go to another group, using members of the
vulnerable group as participants is potentially an abusive reduction of the participants to “human
subject fodder” [23]. Furthermore, some suggest that dominant research methodologies can
themselves exacerbate vulnerability, and that a focus on developing a culturally safe space for
research is crucial to prevent harm and ensure benefit [24]. 
From a Canadian legal perspective, researchers are likely to have fiduciary responsibilities toward
participants when engaging in clinical research [25]. Along with this fiduciary relationship comes a
duty of care, and a duty not to abuse the power imbalance inherent to the clinician-patient
relationship [26]. A fiduciary relationship has three components: the fiduciary has scope for the
exercise of some discretion or power, the fiduciary can unilaterally exercise that power or discretion
so as to affect the beneficiary’s legal or practical interests, and the beneficiary is peculiarly vulnerable
or at the mercy of the fiduciary holding the discretion or power [26]. As such, the law of fiduciaries is
relevant to decisions regarding vulnerable persons in research. Its relevance to decision-making when
assessing a particular vulnerable person for participation likely depends on the probability of the
proposed research causing harm. The principles of fiduciary law appear to have been subsumed into,
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or are at least reflected in bioethics policy. Nonetheless, the presence of fiduciary responsibility can
act to increase or intensify obligations, as well as the consequences for failing to meet them. 
The Tri-Council Policy Statement
The concept of vulnerability is part of the TCPS2’s overarching principles of Respect for Persons,
Concern for Welfare, and Justice [12]. Vulnerability is defined therein as “a diminished ability to fully
safeguard one’s own interests in the context of a specific research project” [12]. The TCPS2 goes on
to state that potential causes of this include “limited decision-making capacity or limited access to
social goods, such as rights, opportunities and power” [12]. Important mentions of vulnerability exist in
multiple chapters of the TCPS2, and can be reviewed in Table 1.
A few specific mentions of vulnerability are crucial and demand consideration. Article 4.7 is the
primary vulnerability provision, and importantly mentions that vulnerability depends on the context of
research. It demands that, once vulnerability is established in said context, a potential participant
should neither be “inappropriately included” not “automatically excluded” from research [12]. This
wording could be considered vague, as we have no indication what “inappropriate” is from the
document. Vagueness of this type is common in bioethics policy documents, and while it may grant a
wide berth of discretion to governing bodies, it also can lead to confusion and/or undue caution
among researchers.
Within Chapter 1 is a list of groups “historically” considered vulnerable. This list includes extremely
broad categories such as “women” and “the elderly” [12]. Yet, in Chapter 4 the TCPS2 prohibits
stereotyping based solely on assumptions about a group to which a participant belongs, and reiterates
the situational nature of vulnerability [12]. Chapter 3 speaks to the requirements of informed consent
when dealing with vulnerable persons. If there is a suspicion that an individual lacks capacity or may
be unduly influenced in the consent process, special steps must be taken: these include, inter alia,
demonstrating minimal risk and demonstrating that the research is being carried out for the direct
benefit of the participant [12].
Chapter 9 appears to place the onus on researchers to find ways to include in research persons from
vulnerable groups within specific or isolated territorial or organizational communities [12]. Barriers
often exist in these circumstances, but such communities also often have the most to gain from the
benefits of research [12]. Finally, Chapter 11 requires clinician-researchers to avoid overstating the
benefits of research and to avoid therapeutic misconception, which occurs when participants
mistakenly believe that the research is legitimate medical treatment even though there may be no
clinical benefit whatsoever [12].
Overall, the TCPS2 broadly addresses many of the issues that have been noted around the traditional
ethics of vulnerability, but does so at the cost of clarity and precision. This lack of precision could
cause a chilling effect on the amount of research performed using PWID, which, as we will discuss in
a later section, could result in harm.
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Table 1 - Highlights: Mentions of Vulnerability in the Tri-Council Policy Statement
Chapter Statement / Comment
1 Respect for Persons requires involving individuals in circumstances of vulnerability in decision 
making where possible. This may include asking about their feelings regarding participation and/or
for their assent.
1 Vulnerability is often caused by limited decision-making capacity, or limited access to social 
goods, such as rights, opportunities and power. Individuals or groups in vulnerable circumstances 
have historically included children, the elderly, women, prisoners, those with mental health issues 
and those with diminished capacity for self-determination. Ethnocultural minorities and those who 
are institutionalized are other examples of groups who have, at times, been treated unfairly and 
inequitably in research, or have been excluded from research opportunities. People or groups 
whose circumstances cause them to be vulnerable or marginalized may need to be afforded 
special attention in order to be treated justly in research.
2 [Vulnerable persons’] inclusion in research should not exacerbate their vulnerability (see Article 
4.7).
3 When participants are vulnerable to risks from third parties (e.g., authoritarian regimes, gang 
leaders, employers) on account of their involvement in research, researchers should ensure that 
copies of field materials are kept in secure locations. 
3 In considering the need for an alteration to consent requirements, researchers and REBs should 
also consider whether the prospective participants (as individuals, groups, or populations) are in 
vulnerable circumstances (see Article 4.7). The existence of vulnerable circumstances may 
require greater effort to minimize risks to participants and/or maximize potential benefits (see 
Chapter 2, Section B).
3 Respect for Persons and Concern for Welfare entails particular ethical obligations to individuals in 
vulnerable circumstances. Such obligations often translate into special procedures to promote and
protect their interests. This may include the development of consent materials that are appropriate
to the cognitive and communication abilities of prospective participants. 
4 In addition to the vulnerability that arises from their developmental stage, children may also lack 
the decision-making capacity to decide whether or not to participate in research (see Article 4.6).
4 [Article 4.7] Individuals or groups whose circumstances may make them vulnerable in the 
context of research should not be inappropriately included or automatically excluded from 
participation in research on the basis of their circumstances.
4 Individuals should not automatically be considered vulnerable simply because of assumptions 
made about the vulnerability of the group to which they belong. Their particular circumstances 
shall be considered in the context of the proposed research project.
4 Researchers should anticipate, to the best of their ability, needs of participants, groups and their 
communities that might arise in any given research project. Especially when groups, and their 
communities, have a wide range of pressing needs due to their low socioeconomic circumstances,
these needs can present significant ethical challenges for researchers. An equitable distribution of 
research benefits (discussed below) can help ensure that individuals, groups and communities 
whose circumstances may make them vulnerable in the context of research are not 
inappropriately included in research based on these circumstances.
9 Groups or individuals whose circumstances may make them vulnerable or marginalized within 
territorial or organizational communities should not be deprived of opportunities to participate in, 
and influence, research affecting their welfare. For example, people living with HIV/AIDS, 
impoverished youth or women who have suffered abuse may experience barriers to participation.
9 Structural barriers may prevent access to, and participation in, research. […] The least 
organizationally developed communities are the most vulnerable to exploitation. Research 
undertaken in these circumstances should strive to enhance capacity for participation.
11 It is important that clinician-researchers take care not to overplay the benefits of research 
participation to patients in vulnerable circumstances, who may be misled to enter trials with false 
hopes. 
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Vulnerability in Clinical Research on Intravenous Drug Users
Determining the vulnerability of PWID is a nuanced task because there is no consistent and inherent
physical vulnerability within the population. Instead, vulnerabilities can arise from multiple
psychological and social factors. Importantly, drug abuse disproportionately affects poor, male, urban
and ethnic minority persons [27-29]. These persons can be doubly vulnerable due to historical and
current institutional forms of oppression that further diminish autonomy and increase risk of
disease [29-31]. Lack of knowledge and education also contributes to vulnerability: for example, one
Canadian study found that, among illicit drug users who tested positive for hepatitis C virus in two
Canadian community clinics, the most common reason for not seeking treatment was a lack of
information about the virus or available treatments [32].
The most obvious questions regarding recruiting PWID for research revolve around the ability to give
informed consent [33]. These participants are potentially at risk of experiencing undue influence on
decision-making due to intoxication, cognitive deficits from long-term substance abuse, comorbid
psychiatric disorders, and other factors [29]. Even when research does not involve the administration
of addictive substances, there is a risk that participation will be unduly coerced in the addicted
participant’s mind due to the desire to acquire the resources, e.g., money, needed to obtain addictive
substances [34]. Fry and colleagues [35] suggest that payments should not be provided as a reward
for risk or harm, should be scrutinized when they could create additional risks, and should only be
provided for any time and out-of-pocket expenses spent on the study.
It has also been suggested that currency should not be provided as compensation to PWID, and
should be substituted with items like vouchers or food [34,36]. Yet, such compensation reflects
negative stereotypes about these participants’ irresponsibility and untrustworthiness, and places
researchers in a moralistic position that both fails to afford research participants the respect of control
and reinforces negative stigma [34,37]. Although more research is needed, studies have found that
neither the mode, i.e., cash or gift certificates, nor the magnitude of payment had a significant effect
on rates of new drug use or perceptions of coercion [35,36,39]. One study found “no evidence that
payment is coercive, undermines voluntariness, or increases drug use in the short-term” [38].
Moreover, payment is an important motivating factor for reaching substance users and maintaining
their attendance at follow up visits [38-41]. This is consistent with general population studies on the
effects of payment: e.g., one study found that approximately 30% of participants in a large controlled
trial reported money as the main motivation for participating, but less than 5% felt the financial
incentive was coercive [40]. Monetary incentives also carry the extra benefit of helping to dispel
therapeutic misconception [29]. Assumptions about reasons for participating in research of PWID
often fail to account for evidence that they participate in part with the hope of benefiting others [42]. At
least two studies show that such individuals, except when intoxicated, are approximately as capable
of making rational decisions to participate in research as non-substance abusing participants, so long
as the study does not involve administration of addictive substances [29,43,44]. 
Nonetheless, the possibility of intoxication at the time of obtaining consent poses a serious risk to any
clinical study. Alcohol intoxication, for example, has been shown to affect suggestibility, risk-taking
and moral reasoning [45]. Intoxication is not a straightforwardly identifiable state that can be easily
measured using biochemical methods; it depends upon individual differences, inter alia [45]. More
empirical research is needed to establish the effects of intoxication by various drugs, or combinations
thereof. Suggestions for ensuring proper consent when faced with potential intoxication include
checking understanding, extending the timeframe for consent and its withdrawal, training staff to
check for signs of intoxication, and excluding from the outset those who are obviously
intoxicated [45,46].
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Discussion
It is clear that special procedures are necessary when engaging in research with PWID. Perhaps the
most important procedures are ensuring the presence of a person independent of the research team
to seek consent, screening for signs of intoxication, and checking comprehension through
questioning. Yet, many concerns about recruitment incentives and the ability to give informed consent
may be inflated. Fisher found that street drug users “share with investigators an appreciation for
foundational moral principles guiding research regulation” and that they “have the ability and
willingness to grapple with core dimensions of morality” [47]. In hindsight, it is possible that some
policies for treatment of “vulnerable persons” are historically founded, in part, in discriminatory (racist,
classist, sexist, etc.) presumptions [48]. The recent literature has been quite critical of existing
research ethics practices surrounding vulnerability. 
Some critics suggest that there is no logical or
empirical basis to certain common categorizations of
vulnerability, and that they are often overbroad [49,50].
Indeed, many foundational documents of bioethics
enumerate lists of vulnerable groups, but lack any
explanation or analysis as to why they are vulnerable
[12,50]. For example, pregnant women are consistently
categorized as vulnerable in many jurisdictions, even in
the face of evidence that this is mostly not the case
[49]. Such categorizations may have a cascading
effect, as, over time, women in general may be
stigmatized as vulnerable and suffer as well [49,51].
This broad stigmatization has potentially been wrongly
imposed on PWID, given aforementioned evidence
indicating that any given individual is likely to be
capable of informed consent [29,43,44].
Paternalism is a related issue. Juritzen posits that
government control through ethics committees and
their associated “pastoral power” molds researchers
into self-regulating agents that are prone to
paternalistic attitudes [52]. As such, the application of
ethical principles in decisions surrounding the inclusion
or exclusion of vulnerable subjects often fails to
account for the perspective and ethics of the subjects
themselves [53,54]. The perspectives of PWID could
be used to identify nonobvious consequences of
specific research practices, such as participant
distress, violation of privacy or diminishment of
autonomy [29,37]. 
Persons categorized as belonging to vulnerable groups are potentially harmed, and rendered more
vulnerable, by their exclusion from research [55,56]. This harm is caused due to a resultant failure to
understand these groups and provide them with the benefits of research [57]. Examples of identified
affected groups include pregnant women and the obese [49,51,57]. The TCPS2 evidently tries to
address this issue in article 4.7, where it states that vulnerable people should not be automatically
excluded from research. However, it is questionable whether this is enough to prevent the
compounding effect of vulnerability, given the fact that extra funds and resources must be applied to
actively include vulnerable persons and to satisfy the TCPS2’s special requirements for informed
consent that accompany their inclusion [57]. There is often a financial disincentive to including
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Selected Critical Quotes from the 
Literature
…this erroneous characterization of pregnant 
women as “vulnerable” and its associated 
protections have not only impeded vital 
research for pregnant women and their 
fetuses, but have also negatively affected the 
inclusion of all women in clinical research. 
-Schonfeld, 2013
…regulators and institutional review boards 
(IRBs) often target groups for protections; but 
in reality we are dealing with unique 
individuals who have become part of a 
heterogeneous group only because of the 
sampling intentions of a researcher. 
-Dubois et al, 2012
…the paternalistic attitudes that prevent 
vulnerable people from being recruited into a 
study are also denying them their basic right 
to autonomy, their right to decide for 
themselves whether or not to participate in a 
study, as well as exposing them to the risk of 
marginalization. -Alexander, 2010
Several foundational documents of bioethics 
mention the special obligation researchers 
have to vulnerable research participants. 
However, the treatment of vulnerability offered
by these documents often relies on 
enumeration of vulnerable groups rather than 
an analysis of the features that make such 
groups vulnerable. -Lange, 2013
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vulnerable groups in research, and when combined with paternalistic attitudes this can prevent
vulnerable groups from being studied. Fear of potential legal liability under fiduciary law can further
dissuade researchers from including vulnerable participants. It is unclear to what extent PWID,
already severely disadvantaged, have been harmed through exclusion from research. For example, it
is unclear whether their rate of disease is higher due to a lack of access to the education afforded by
participation in research [32].
Major research undertakings can be relocated to more lenient jurisdictions abroad in order to carry out
research deemed high risk or problematic at home [58,59]. This “research tourism” is a potential pitfall
of restrictive policies towards research on vulnerable populations. The Helsinki Declaration helps
diminish this problem by providing consistent overarching guidelines, but fails to solve it. In instances
where research is undertaken in other jurisdictions, vulnerable persons may be slow to receive the
benefits of research, or may fail to receive them altogether.
Conclusions 
In our view, the likelihood that harm is caused by the exclusion from research of persons who are
broadly stereotyped as vulnerable creates an imperative to collect better data as to the effects of
relevant research ethics policies. In Canada, the broad nature of the TCPS2 creates space for
significant discretionary action by research ethics boards. This top down approach may often be
based more on principles and hypotheticals than data. Further empirical research into the effects of
excluding vulnerable persons like PWID from clinical research would help to either address or support
serious existing criticisms of current systems [37,60]. It seems only logical that we collect data about
the consequences of established ethical standards in science, rather than relying on historical beliefs
as to the proper application of axioms [37,60]. Simply engaging in this type of research will help to
alleviate concerns of paternalism, because such research would certainly focus on the experiences,
perspectives and needs of research participants [61]. Such engagement could be facilitated through
collaborative work between medical and social science researchers, and might for example include
interviewing and surveying of persons subsequent to ethics-based exclusion from particular research
projects. On a larger scale, further study of rates of research participation could prove useful,
especially if data is then related to rates of health and disease as compared to baseline populations.
Local substance abuse organizations would be important contact points for establishing fruitful
relationships.
Ensuring that PWID and other vulnerable persons are recruited for clinical research is a shared
responsibility of both researchers and frontline healthcare providers [56,62]. However, administrative
guidelines act to discourage or prohibit such recruitment. We suggest that research ethics boards in
Canada adopt a more evidence-based approach when applying their discretionary power to proposals
for clinical research. As more data on the consequences of specific research policies is collected,
evidence-informed policy options will emerge that can guide changes to the future of Canadian clinical
research ethics. 
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Potential Benefits and Harms of Research on PWID
Potential Benefits Potential Harms
Generation of new clinical knowledge, more 
rapidly
Therapeutic misconception
Reduction in disease in PWID populations Undue influence to participate in risky research
Increased PWID resources through education Physical harm due to clinical error
Increased PWID resources through 
compensation
Increase in addiction due to acquisition of resources
Better understanding of issues specific to 
PWID
Paternalism, and related failure to meet the needs of 
PWID
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